Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pancreatic cancer
Stage/Subtype:  stage II pancreatic cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 40 for your search:
Start Over
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NLG0505, NCI-2013-01044, 1210-1195, NCT01836432
Surgery With or Without Intraperitoneal Drainage in Improving Complication Rate in Patients With Pancreatic Disease
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: H-28324, NCI-2012-01881, NCT01441492
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-PANC-003, NCI-2014-00810, 2013-003398-91, NCT01964430
Gemcitabine Hydrochloride and Hydroxychloroquine Before Surgery in Treating Patients With High Risk Stage IIB-III Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 19 and over
Trial IDs: 09-122, NCI-2011-02492, NCT01128296
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Erismodegib before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1130, NCI-2012-00064, CIR00003888, LDE225XUS03T, NA_00047491, NA_00047491 / CIR00004443, NCT01431794
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Capecitabine, Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Stage II-III Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAD6491, NCI-2010-00829, NCT01065870
Vaccine Therapy and Cyclophosphamide in Treating Patients with Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J09100, NCI-2010-01868, CIR00005394, NA_00031401, NCT01088789
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-TORI PA-01, NCI-2010-02190, NCT01234935
Stereotactic Radiosurgery in Treating Patients with Pancreatic Cancer That Has Been Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-123, NCI-2014-01951, NCI-2014-01140, NCT01357525
Proton or Photon Beam Radiation Therapy, Capecitabine, and Hydroxychloroquine in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-073, NCI-2012-00148, NCT01494155
Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Patients with High-Risk Pancreatic Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2011-1208, NCI-2012-00571, NCT01560949
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients with Pancreatic Cancer That May Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2011.007, NCI-2012-01916, HUM00047389, HUM 47389, NCT01661088
Combination Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1105, NCI-2013-01059, NCT01688336
Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-570, NCI-2013-01213, 12-017, NCT01897454
Combination Chemotherapy with or without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients with Locally Advanced Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 441-13, NCI-2013-02273, NCI-2012-00835, NCI-2013-02118, NCT01959672
Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Hydroxychloroquine Before Surgery in Treating Patients With Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 13-074, NCI-2013-02230, NCT01978184
Gemcitabine Hydrochloride and Nab-Paclitaxel or mFOLFIRINOX with Stereotactic Body Radiation Therapy before Surgery in Treating Patients with Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: UPCI# 13-143, NCI-2014-02046, PRO13120167, NCT02241551
PEGPH20, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Borderline Resectable Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 144515, NCI-2015-01213, 121697, NCT02487277
Low-Sugar Diet in Treating Patients With Stage II-III Pancreatic Cancer Undergoing Chemoradiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201102772, NCI-2012-00326, 01110101, NCT01419483
Romidepsin in Treating Patients with Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors with Liver Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11105, NCI-2012-01040, CDR0000737061, NCI-2013-01545, P9008_A10PAMDREVW01, 9008, NCT01638533
Sorafenib Tosylate and Capecitabine in Treating Patients With Advanced Breast or Gastrointestinal Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HIC # 1112009424, NCI-2013-00893, 1112009424, ONC-2010-35, NCT01640665
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: RT-054, NCI-2012-02729, 12-046, NCT01739439
Start Over